NIKA PHARMACEUTICALS, INC
Nika Pharmaceuticals is a pharmaceutical company focused on developing, producing and distributing prescription medicines and dietary supplements. Its products include Thymus Nuclear Glycoprotein (TNG), a prescription drug, and the dietary supplements Carotilen and Physiolong. The company also has exclusive rights to produce and sell six additional supplements: Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C and Silymaron. It is working with Immunotech Laboratories BG on medicinal products based on the Inactivated Pepsin Fraction platform. Nika makes money through the production and sale of medicines and supplements under its rights agreements and joint arrangements. It holds an 80% controlling interest in Nika Europe, Ltd., which is preparing a pharmaceutical factory for manufacturing drugs in injection, tablet and other forms. Nika Pharmaceuticals was incorporated in Colorado and is headquartered in Henderson, Nevada.
No SEC Form 4 filings for $NIKA in the last 30 days.
See all $NIKA insider activity →Nika Pharmaceuticals reported no revenue and a widened net loss for 3Q 2026, with higher general and administrative costs and increased professional fees. The company's expenses rose due to OTC Markets fees and legal costs, according to its 10-Q filing.
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) projects €8.5 Billion revenue from its distribution agreements for Nigeria, Ukraine, UAE, Iraq, Syria, and Jordan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NIKA (NIKA PHARMACEUTICALS, INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent NIKA coverage spans earnings and financial news.
The quarterly loss and lack of revenue may pressure the stock, reflecting higher G&A and legal costs.
Nika Pharmaceuticals projects €8.5 billion revenue from distribution agreements across multiple regions, indicating strong growth prospects.
AlphAI scores every news story that mentions NIKA with an AI model for sentiment and relevance, and aggregates insider trades from NIKA PHARMACEUTICALS, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Nika Pharmaceuticals reported no revenue and a widened net loss for 3Q 2026, with higher general and administrative costs and increased professional fees. The company's expenses rose due to OTC Markets fees and legal costs, according to its 10-Q filing.
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) projects €8.5 Billion revenue from its distribution agreements for Nigeria, Ukraine, UAE, Iraq, Syria, and Jordan.
